The C-terminal amidated analogue of the substance P (SP) fragment SP(1-7) attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats. 2009

Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
Department of Pharmaceutical Biosciences, Division of Biological Research on Drug Dependence, Uppsala University, S-751 24 Uppsala, Sweden.

We previously demonstrated that intracerebroventricular (i.c.v.) administration of the substance P (SP) aminoterminal fragment SP(1-7) attenuates the expression of morphine withdrawal in the male rat. In this study we have used a synthetic analogue of this peptide, i.e. the SP(1-7) amide showing higher binding potency than the native heptapeptide, in a similar experimental set-up. Thus, Wistar male rats were made tolerant to morphine by daily injections of the opiate during 8 days. Following peptide administration (i.c.v.) and a subsequent naloxone challenge a variety of physical syndromes of withdrawal were recorded. We observed that the SP(1-7) amide potently and dose-dependently reduced several signs of reaction to morphine withdrawal. Interestingly, the effect of the peptide amide was significantly attenuated by the addition of the sigma agonist (+)-SKF-10047. We conclude that the SP(1-7) amide mimics the effect of the native SP fragment and that the mechanisms for its action involve a sigma receptor site.

UI MeSH Term Description Entries
D008297 Male Males
D009021 Morphine Dependence Strong dependence, both physiological and emotional, upon morphine. Morphine Abuse,Morphine Addiction,Abuse, Morphine,Addiction, Morphine,Dependence, Morphine
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010620 Phenazocine An opioid analgesic with actions and uses similar to MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1095) Phenbenzorphan,Phenethylazocine,Narphen,Phenazocine Hydrobromide,Hydrobromide, Phenazocine
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013373 Substance P An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses. Euler-Gaddum Substance P,Hypothalamic Substance P,SP(1-11),Euler Gaddum Substance P,Substance P, Euler-Gaddum,Substance P, Hypothalamic
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
January 1986, The Journal of pharmacology and experimental therapeutics,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
May 1995, European journal of pharmacology,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
April 2024, Psychopharmacology,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
December 2014, Psychopharmacology,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
August 2001, Brain research,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
January 2009, Behavioural brain research,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
July 1993, European journal of pharmacology,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
December 1998, Neuropharmacology,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
January 1989, Life sciences,
Qin Zhou, and Anna Carlsson, and Milad Botros, and Rebecca Fransson, and Anja Sandström, and Torsten Gordh, and Mathias Hallberg, and Fred Nyberg
April 2015, Behavioural pharmacology,
Copied contents to your clipboard!